Lymph directing prodrugs
US-2024050573-A1 · Feb 15, 2024 · US
Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists
US9889101B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9889101-B2 |
| Application number | US-201213418193-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2012 |
| Priority date | Jan 27, 2009 |
| Publication date | Feb 13, 2018 |
| Grant date | Feb 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.
First claim
Opening claim text (preview).
We claim: 1. A method for treatment of cervical or vaginal cancer or their associated cervical intraepithelial neoplasia I-III (CINI-III) and vaginal intraepithelial neoplasia I-III (VINI-III)), comprising administering an effective amount of an estrogen antagonist therapy to a human patient having cervical intraepithelial neoplasia (CINI-III) and vaginal intraepithelial neoplasia I-III (VINI-III), wherein the estrogen antagonist therapy is a selective estrogen receptor modulator that has estrogen receptor-antagonistic effects and does not have receptor-agonist effects in cervical or vaginal tissue and that is effective to decrease cancer lesion size, reduce, resolve, or halt progression or reoccurrence of the cancerous or precancerous lesions thereof, thereby treating the cervical intraepithelial neoplasia (CINI-III) and vaginal intraepithelial neoplasia I-III (VINI-III). 2. The method of claim 1 wherein the estrogen antagonist therapy is fulvestrant. 3. The method of claim 2 wherein the estrogen antagonist therapy is administered at a loading dose of 500 mg (±10%) on day 1 and 14 and monthly dosing of either 250 mg (±10%) or 500 mg (±10%). 4. The method of claim 1 wherein the estrogen antagonist therapy is raloxifene.
Assignees
Inventors
Classifications
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
Non condensed piperidines, e.g. piperocaine · CPC title
- A61K31/138Primary
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
Antineoplastic agents · CPC title
specific for metastasis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9889101B2 cover?
- A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms …
- Who is the assignee on this patent?
- Lambert Paul F, Chung Sanghyuk, Wisconsin Alumni Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61K31/138. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).